November 1, 2023 03:14 PM EDTUpdated 04:58 PM
Pharma
FDA+

Am­gen’s win for a Ste­lara in­ter­change­able biosim­i­lar prompts ques­tions about ‘mean­ing­ful com­pe­ti­tion’ un­der IRA

Nicole DeFeudis

Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

It's been three months with­out a biotech IPO

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

A service from the Financial Times